Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen M MooreMichael A BookmanJalid SehouliAustin MillerCharles AndersonGiovanni ScambiaTashanna MyersCagatay TaskiranKatina RobisonJohanna MaenpaaLyndsay WillmottNicoletta ColomboJessica Thomes-PepinMichalis LiontosMichael A GoldYolanda GarciaSudarshan K SharmaChristopher J DarusCarol AghajanianAikou OkamotoXiaohua WuRustem SafinFan WuLuciana L MolineroVidya MaiyaVictor K KhorYvonne G LinSandro PignataPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Current evidence does not support the use of immune checkpoint inhibitors in newly diagnosed OC. Insight from this trial should inform further evaluation of immunotherapy in OC.